Abstract: Objective To observe the efficacy and safety of lobaplatin（LBP） combined with etoposide or irinotecan for patients with advanced small cell lung cancer（SCLC）. Methods Forty-five patients with histologically diagnosed SCLC were divided into two groups. The LE regimen group（lobaplatin 30mg／m² iv d₁， VP-16 100mg iv d₁-d₃，21 days were a cycle） had 25 patients and the LI regimen group（lobaplatin 30mg／m² iv d₁， irinotecan 60 mg／m² iv d₁，d₈，d₁₅，28 days were a cycle） had 20 patients. The efficacy and toxicity were evaluated after at least two cycles of chemotherapy. Results Forty-five patients were evaluable for response， in which 2 achieved complete response（CR）， 24 partial responses（PR）， and the response rate（RR） was 57.8％. The RR in LE regimen group was 48.0％（12／25）， while in LI regimen group was 70.0％（14／20）. The median overall survival（OS） of LE regimen and LI regimen were 8.0 months and 7.0 months， respectively（P=0.255）. The main toxicities were reversible bone marrow suppression and gastrointestinal reaction. Grade 3-4 thrombocytopenia rate was 17.8％（8／45）， the occurence rate was higher in LI regimen than LE regimen（30.0％ vs. 8.0％， P=0.002）. All grade 3-4 diarrhea was all occurred in patients with LI regimen（8.9％，4／45）, who were retreated patints too. There was no treatmentrelated death. Conclusion Lobaplatin combined with etoposide or irinotecan is effective and tolerated for patients with advanced small cell lung cancer，and worth further study.